X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The Innovate UK grant will allow STORM to develop a drug acting on a key coronavirus protein that is not targeted by current treatments. Generation of such a drug will provide a valuable option for treating Covid-19 and other coronavirus diseases.
Lead Product(s): Undisclosed
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Small molecule
Recipient: Storm Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Funding May 03, 2022
Details:
The fund will be used to further develop Innovate's proprietary IGEG platform. IGEG antibodies combine key structural elements of both IgE and IgG antibodies into a novel and proprietary antibody structure.
Lead Product(s): Mov18 IgE
Therapeutic Area: Oncology Product Name: Mov18 IgE
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: U.K Government
Deal Size: $0.6 million Upfront Cash: Undisclosed
Deal Type: Funding July 21, 2020
Details:
Innovative to change its name to 9 Meters Biopharma. 9 Biopharma meters to focus on delivering novel approach including the first and only long-acting GLP-1 agonist receptor for Short Bowel Syndrome.
Lead Product(s): Larazotide Acetate
Therapeutic Area: Gastroenterology Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Peptide
Partner/Sponsor/Collaborator: RDD Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Merger April 30, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
